Lysteda Fails To Improve Traumatic Brain Injury Recovery: Study

The clotting drug Lysteda failed to provide any significant improvement in patients suffering from traumatic brain injury, according to the findings of a new study.

Lysteda (tranexamic acid) is used to help prevent bleeding and hemorrhage among patients with certain conditions, such as bleeding disorders. It is used to prevent and reduce bleeding major surgery, pulling teeth, or to stop heavy menstrual bleeding.

Researchers from Duke University hypothesized giving Lysteda to head injury patients could help reduce brain bleeds and help improve their recovery.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

However, according to findings of a study published in the Journal of the American Medical Association (JAMA) on September 8, treating patients with Lysteda in the ambulance before they reach the hospital and while at the hospital did not help improve their disability or death rates,

Researchers at Duke University conducted a randomized multi-center clinical trial at 20 trauma centers in the United States and Canada from May 2015 to November 2017. The study included 966 patients over the age of 15 with moderate to severe traumatic brain injury who were enrolled within two hours of injury.

The study used three interventions to evaluate the use of tranexamic acid, or Lysteda. One group was treated with 1 g of Lysteda by paramedics then given 1 g of Lysteda at the hospital using an 8-hour infusion. The second groups was given 2 g of Lysteda by paramedics and an in-hospital 8-hour infusion of a placebo. The third group was given a placebo by the paramedics and an 8-hour infusion placebo at the hospital.

On average, patients had a Glasgow Score of 8, which is a neurological scale used to assess a person’s consciousness. A score of 3 would indicate deep unconsciousness and 15 indicating completely alert with no issues.

Overall, 65% of patients who took Lysteda had a lower Glasgow score. Comparatively, 62% of patients in the placebo group had a lower score, which researchers determined was not a statistically significant difference.

The data also indicated there was no statistical difference for 28 day death rates, six month disability rating scores, or progression of intracranial hemorrhage.

Researchers argue the small statistical difference seen could mean the difference of reducing deaths by 560 people per year, based on an estimated 56,000 TBIs occurring in the U.S each year. Or if the absolute reduction in the study was real it could possibly reduce all cause mortality by 1,6000 deaths each year.

More research would be needed to determine if the small statistical difference was accurate among all patient populations or was only a factor in this case.

Traumatic brain injury, or a typical concussion, is the leading cause of death and disability due to trauma in the United States. Patients who suffer TBIs have an increased risk of suicide later and an increased risk of developing Dementia.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted yesterday)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted yesterday)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.

Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant
Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant (Posted 2 days ago)

Following a $60 million verdict in a similar lawsuit earlier this year, trial is underway involving claims brought by an Illinois mother, whose premature daughter developed NEC from Similac, alleging that Abbott failed to warn parents and medical staff of the devastating risks associated with the cow's milk-based formula.